A Randomized Pilot Study to Investigate the Safety and Immunologic Impact of Evolocumab When Given in Combination With Ipilimumab and Nivolumab in Treatment-Naïve Patients With Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Evolocumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TOP2101
- 18 Jul 2024 Planned End Date changed from 1 Dec 2025 to 1 Jun 2027.
- 18 Jul 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2025.
- 16 May 2022 Status changed from not yet recruiting to recruiting.